ライフサイエンスコーパス: palifermin

1 tis in the placebo group received open-label palifermin.

2 quent cycles (a total of 17) with open-label palifermin.

3 ts received placebo and 28 patients received palifermin.

4 patients reported less severe symptoms with palifermin.

5 Palifermin (180 microg per kg of body weight) or placebo

6 Six patients (placebo = 2, palifermin = 4) experienced a total of 11 dose-limiting

7 ndomly assigned to receive either placebo or palifermin (40 microg/kg for 3 consecutive days) before

8 Patients were randomly assigned 2:1 to palifermin 60 microg/kg or placebo once weekly for 10 do

9 ors to receive either recombinant human KGF (palifermin 60 mug/kg) or placebo (0.9% sodium chloride s

10 h hematologic cancers; 106 patients received palifermin (60 microg per kilogram of body weight per da

11 verse events were similar between arms (98%, palifermin; 93%, placebo).

12 Palifermin (a recombinant human keratinocyte growth fact

13 Palifermin, a recombinant human keratinocyte growth fact

14 Palifermin administered at the indicated dosing regimen

15 Sixty-seven patients received palifermin and 32 received placebo.

16 rty-nine reports met the inclusion criteria: palifermin and dexrazoxane, three reports (two studies)

17 or= 2 mucositis was 6.5 and 8.1 weeks in the palifermin and placebo groups, respectively (P = .157).

18 Palifermin appeared to reduce mucositis, dysphagia, and

19 In the palifermin arm, median time to severe OM was delayed (47

20 Ten once-weekly doses of palifermin at 60 microg/kg were well tolerated.

21 A single dose of palifermin before each cycle reduced the incidence and s

22 Palifermin can be considered as the prototype mitigant.

23 higher OM was lower in patients who received palifermin compared with placebo (29% v 61% in cycle 1;

24 Palifermin did not alter tumor response or survival.

25 Most patients completed treatment, but palifermin did not reduce the morbidity of concurrent ch

26 Palifermin doses were 40 mug/kg per day (cohort 1 only)

27 Future studies should evaluate higher palifermin doses with longer and more standardized asses

28 quent in the placebo group (31%) than in the palifermin group (14%).

29 cycles (range, 1 to 6) were completed by the palifermin group and 2 (range, 1 to 6) by the placebo gr

30 de 3 or 4 was 3 days (range, 0 to 22) in the palifermin group and 9 days (range, 0 to 27) in the plac

31 mucositis was 6 days (range, 1 to 22) in the palifermin group and 9 days (range, 1 to 27) in the plac

32 ion (WHO) grade 3 or 4 was 63 percent in the palifermin group and 98 percent in the placebo group (P<

33 s were thickening of oral mucosa (72% in the palifermin group vs. 31% in the placebo group; P = 0.007

34 grade >/= 2 was lower (67% v 80%), favoring palifermin; however, the differences were not significan

35 is study assessed the efficacy and safety of palifermin in patients receiving concurrent chemoradioth

36 who had severe mucositis received open-label palifermin in subsequent cycles.

37 hese results support the clinical benefit of palifermin in the HSCT setting, providing evidence that

38 Palifermin is recommended to decrease severe mucositis i

39 tudy assessed the safety and tolerability of palifermin (n = 69) as compared with placebo (n = 31) in

40 The palifermin (n = 94) and placebo (n = 94) arms were well

41 randomly assigned in a 2:1 ratio to receive palifermin or placebo.

42 We tested the ability of palifermin (recombinant human keratinocyte growth factor

43 Although palifermin reduced severe functional OM, its role in the

44 Compared with placebo, palifermin reduced the cumulative incidence of moderate

45 Palifermin reduced the duration and severity of oral muc

46 Palifermin reduced the incidence and duration of severe

47 Palifermin reduces mucositis when given in multiple dose

48 Patients receiving palifermin reported statistically significant improvemen

49 nce of severe OM was significantly lower for palifermin than for placebo (54% v 69%; P = .041).

50 d study evaluated the efficacy and safety of palifermin to reduce OM associated with definitive chemo

51 investigation is needed to determine whether palifermin use will facilitate greater adherence to chem

52 Palifermin was associated with reduced incidence and mea

53 As compared with placebo, palifermin was associated with significant reductions in

54 We conclude that palifermin was generally safe in allogeneic HSCTs but ha

55 Overall, palifermin was safe and well tolerated.

56 is double-blind study compared the effect of palifermin with that of a placebo on the development of